Cargando…
SURINPARK: Safinamide for Urinary Symptoms in Parkinson’s Disease
Background: Urinary symptoms are common, disabling and generally unresponsive to treatment in Parkinson´s disease (PD). Safinamide is approved as an add-on therapy to levodopa to improve fluctuations. Methods: Retrospective analysis of electronic records of nondemented PD patients seen consecutively...
Autores principales: | , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7825064/ https://www.ncbi.nlm.nih.gov/pubmed/33418858 http://dx.doi.org/10.3390/brainsci11010057 |
_version_ | 1783640223027036160 |
---|---|
author | Gómez-López, Ana Sánchez-Sánchez, Arantxa Natera-Villalba, Elena Ros-Castelló, Victoria Beltrán-Corbellini, Álvaro Fanjul-Arbós, Samira Pareés Moreno, Isabel López-Sendon Moreno, José Luis Martínez Castrillo, Juan Carlos Alonso-Canovas, Araceli |
author_facet | Gómez-López, Ana Sánchez-Sánchez, Arantxa Natera-Villalba, Elena Ros-Castelló, Victoria Beltrán-Corbellini, Álvaro Fanjul-Arbós, Samira Pareés Moreno, Isabel López-Sendon Moreno, José Luis Martínez Castrillo, Juan Carlos Alonso-Canovas, Araceli |
author_sort | Gómez-López, Ana |
collection | PubMed |
description | Background: Urinary symptoms are common, disabling and generally unresponsive to treatment in Parkinson´s disease (PD). Safinamide is approved as an add-on therapy to levodopa to improve fluctuations. Methods: Retrospective analysis of electronic records of nondemented PD patients seen consecutively in a Movement Disorders Unit (November 2018–February 2019). All were assessed with Scale for Outcomes in Parkinson’s disease for Autonomic Symptoms-Urinary subscale (SCOPA-AUT-U) by the attending neurologist, and a month afterwards by an independent researcher blinded to treatment and clinical records in a routine clinical practice setting. Clinical variables were compared among patients who were prescribed safinamide (SA+) for the treatment of motor fluctuations and those with different treatment regimes (SA−). Results: From 169 patients screened initially, 54 were excluded due to severe incontinence, absence of urinary symptoms or previous safinamide treatment. Thirty-five patients were included in SA+ and 79 in SA−. Both groups were comparable in terms of clinical variables, except in basal urinary symptoms, with more severity in the SA+ group. In the follow-up assessment, total SCOPA-AUT-U, as well as urgency, incontinence, frequency and nocturia subscales improved significantly in the SA+ group, while the SA− group remained unchanged. Conclusions: Safinamide could be helpful in the improvement of urinary symptoms in PD. |
format | Online Article Text |
id | pubmed-7825064 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-78250642021-01-24 SURINPARK: Safinamide for Urinary Symptoms in Parkinson’s Disease Gómez-López, Ana Sánchez-Sánchez, Arantxa Natera-Villalba, Elena Ros-Castelló, Victoria Beltrán-Corbellini, Álvaro Fanjul-Arbós, Samira Pareés Moreno, Isabel López-Sendon Moreno, José Luis Martínez Castrillo, Juan Carlos Alonso-Canovas, Araceli Brain Sci Article Background: Urinary symptoms are common, disabling and generally unresponsive to treatment in Parkinson´s disease (PD). Safinamide is approved as an add-on therapy to levodopa to improve fluctuations. Methods: Retrospective analysis of electronic records of nondemented PD patients seen consecutively in a Movement Disorders Unit (November 2018–February 2019). All were assessed with Scale for Outcomes in Parkinson’s disease for Autonomic Symptoms-Urinary subscale (SCOPA-AUT-U) by the attending neurologist, and a month afterwards by an independent researcher blinded to treatment and clinical records in a routine clinical practice setting. Clinical variables were compared among patients who were prescribed safinamide (SA+) for the treatment of motor fluctuations and those with different treatment regimes (SA−). Results: From 169 patients screened initially, 54 were excluded due to severe incontinence, absence of urinary symptoms or previous safinamide treatment. Thirty-five patients were included in SA+ and 79 in SA−. Both groups were comparable in terms of clinical variables, except in basal urinary symptoms, with more severity in the SA+ group. In the follow-up assessment, total SCOPA-AUT-U, as well as urgency, incontinence, frequency and nocturia subscales improved significantly in the SA+ group, while the SA− group remained unchanged. Conclusions: Safinamide could be helpful in the improvement of urinary symptoms in PD. MDPI 2021-01-06 /pmc/articles/PMC7825064/ /pubmed/33418858 http://dx.doi.org/10.3390/brainsci11010057 Text en © 2021 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Article Gómez-López, Ana Sánchez-Sánchez, Arantxa Natera-Villalba, Elena Ros-Castelló, Victoria Beltrán-Corbellini, Álvaro Fanjul-Arbós, Samira Pareés Moreno, Isabel López-Sendon Moreno, José Luis Martínez Castrillo, Juan Carlos Alonso-Canovas, Araceli SURINPARK: Safinamide for Urinary Symptoms in Parkinson’s Disease |
title | SURINPARK: Safinamide for Urinary Symptoms in Parkinson’s Disease |
title_full | SURINPARK: Safinamide for Urinary Symptoms in Parkinson’s Disease |
title_fullStr | SURINPARK: Safinamide for Urinary Symptoms in Parkinson’s Disease |
title_full_unstemmed | SURINPARK: Safinamide for Urinary Symptoms in Parkinson’s Disease |
title_short | SURINPARK: Safinamide for Urinary Symptoms in Parkinson’s Disease |
title_sort | surinpark: safinamide for urinary symptoms in parkinson’s disease |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7825064/ https://www.ncbi.nlm.nih.gov/pubmed/33418858 http://dx.doi.org/10.3390/brainsci11010057 |
work_keys_str_mv | AT gomezlopezana surinparksafinamideforurinarysymptomsinparkinsonsdisease AT sanchezsanchezarantxa surinparksafinamideforurinarysymptomsinparkinsonsdisease AT nateravillalbaelena surinparksafinamideforurinarysymptomsinparkinsonsdisease AT roscastellovictoria surinparksafinamideforurinarysymptomsinparkinsonsdisease AT beltrancorbellinialvaro surinparksafinamideforurinarysymptomsinparkinsonsdisease AT fanjularbossamira surinparksafinamideforurinarysymptomsinparkinsonsdisease AT pareesmorenoisabel surinparksafinamideforurinarysymptomsinparkinsonsdisease AT lopezsendonmorenojoseluis surinparksafinamideforurinarysymptomsinparkinsonsdisease AT martinezcastrillojuancarlos surinparksafinamideforurinarysymptomsinparkinsonsdisease AT alonsocanovasaraceli surinparksafinamideforurinarysymptomsinparkinsonsdisease |